Cereno Revenue and Competitors
Estimated Revenue & Valuation
- Cereno's estimated annual revenue is currently $4.5M per year.
- Cereno's estimated revenue per employee is $155,000
Employee Data
- Cereno has 29 Employees.
- Cereno grew their employee count by 7% last year.
Cereno's People
| Name | Title | Email/Phone |
|---|
Cereno Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Cereno?
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study program for CS1 in PAH has obtained a US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca's BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.
keywords:N/A
N/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cereno News
For instance, in 2018, Cereno Scientific had collaborated with CRO 'OCT', with the aim of conducting phase 2 clinical trials to study...
Barangay Bato chairman Rosalio Cereno Jr. assured TVI of their continued support. "We are thankful to TVI for supporting our projects.
Other Companies in Mölndal
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 34 | 3% | N/A |
#2 | $12.9M | 46 | -8% | N/A |
#3 | $9.6M | 48 | -6% | N/A |
#4 | $6.8M | 50 | 4% | N/A |
#5 | $22.7M | 63 | 11% | N/A |